Oncology

< Back

Overview

The Oncology research area is composed by nine groups addressing the principal unsolved issues in cancer. Their research covers fields such as child and adolescent cancer, melanoma, Gynecology, Urology, cancer stem cells and the molecular mechanisms of the tumor pathologies.

There are also three groups from the CIBBIM-Nanomedicine. These groups study the use of nanotechnology in biomedical applications to improve therapeutic strategies and diagnostics.

Publications

125
total
725.353
impact factor
5.803
average impact factor

Group Leader: Joan Morote Robles

Prostate cancer (CaP) is the most common tumor in industrialized countries and the third leading cause of death from cancer in Europe. In 2018, our Group focused on the mechanism of action of the PTOV1 oncogene, discovered by our group and the study of hormone-resistance in metastatic cancer. Analysis of public databases has shown the overexpression of PTOV1 in breast cancer and ovary insensitive to chemotherapy, a higher expression of PTOV1 is significantly associated with worse survival, indicating that PTOV1 is a predictor of response and is a promising therapeutic target in cancer. We have identified a protein domain responsible for its action in chemotherapy-resistant CaP. We have generated models of primary cultures ex vivo of CaP and laryngeal cancer and studied the mechanisms of progression and resistance to therapy. We have tested the signaling pathways in CaP and identified resistance markers in laryngeal cancer.

The biomedical research group led by Dr. Juan Morote maintains a stable collaboration with the Cell Cycle and Cancer group (within the Biomedical Research Group in Gynecology) led by Dr. Anna Santamaria. This collaboration has resulted in the identification of molecules with a relevant role in the acquisition of resistance to hormone therapy and, therefore, in the possibility of studying their potential as new therapeutic targets for the treatment of more aggressive PCa.

VHIR Annual Report 2018